Jonathan Robert Hunt bought $49k of CATX
Chief Financial Officer at Perspective Therapeutics, Inc.. 12,829 shares at an average of $3.82, traded Nov 25, 2024, filed Nov 27, 2024.
Score components
- +22RoleCFO
- +7Trade size$49k at market
- +6Relative to holdingsHoldings up 36%
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -22.6%, 3m -34.2%, 6m -37.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-131250, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 25, 2024 | POpen-market purchase Common Stock | +400 | $3.55 | $1,420 | 36,371 | Nov 27, 2024 |
| Nov 25, 2024 | POpen-market purchase Common Stock | +29 | $3.94 | $114 | 36,400 | Nov 27, 2024 |
| Nov 25, 2024 | POpen-market purchase Common Stock | +2,400 | $3.60 | $8,640 | 38,800 | Nov 27, 2024 |
| Nov 25, 2024 | POpen-market purchase Common Stock | +10,000 | $3.88 | $39k | 48,800 | Nov 27, 2024 |
Related signals
Other insiders at Perspective Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 42Moderate | Perspective Therapeutics, Inc. | Lantheus Alpha Therapy, LLC owner | $777k 247,932 shares | -2% | |
| 35Weak | Perspective Therapeutics, Inc. | Lantheus Alpha Therapy, LLC owner | $357k 113,914 shares | -1% | |
| 31Weak | Perspective Therapeutics, Inc. | Lantheus Alpha Therapy, LLC owner | $131k 42,129 shares | -0% | |
| 30Weak | Perspective Therapeutics, Inc. | Lantheus Holdings, Inc. owner | $112k 35,769 shares | -0% | |
| 33Weak | Perspective Therapeutics, Inc. | Lantheus Holdings, Inc. owner | $246k 78,145 shares | -1% | |
| 37Weak | Perspective Therapeutics, Inc. | Jonathan Robert Hunt Chief Accounting Officer | $22k 11,000 shares | +23% | |
| 41Moderate | Perspective Therapeutics, Inc. | Robert F Williamson III director | $20k 9,498 shares | +2595% | |
| 73Notable | Perspective Therapeutics, Inc. | Juan Graham Chief Financial Officer | $75k 33,333 shares | +1649% | |
| 58Moderate | Perspective Therapeutics, Inc. | Lori A Woods director | $50k 23,475 shares | +15% | |
| 69Notable | Perspective Therapeutics, Inc. | Robert F Williamson III director | $132k 60,337 shares | +124% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.